Jennings Naranjo
Nurse Practitioner · Lufkin, TXNPI 1881164960
Payments from drug & device makers
Across 88 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$324
- Lilly USA, LLC$270
- AbbVie$137
- Boehringer Ingelheim$103
- Amgen$89
- Radius Health, Inc.$72
- plus $507 from 18 others
What the payments were for
- Food & beverage$1,502100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $324 |
| Lilly USA, LLC | 17 | $270 |
| AbbVie | 4 | $137 |
| Boehringer Ingelheim | 7 | $103 |
| Amgen | 6 | $89 |
| Radius Health, Inc. | 4 | $72 |
| Dexcom, Inc. | 3 | $68 |
| AstraZeneca | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $49 |
| Pfizer | 3 | $43 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Tolmar, Inc. | 2 | $34 |
| GSK | 2 | $29 |
| Bayer | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Halozyme Inc | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,502 in reported general payments places this provider in the 80th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $53,964 |
| JardianceEmpagliflozin | 32 | $29,425 |
| EliquisApixaban | 38 | $26,708 |
| MounjaroTirzepatide | 20 | $22,737 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 27 | $19,515 |
| FarxigaDapagliflozin Propanediol | 20 | $12,027 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $7,063 |
| NexletolBempedoic Acid | 14 | $5,376 |
| JanuviaSitagliptin Phosphate | 11 | $5,265 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $4,291 |
| Icosapent Ethyl | 12 | $3,278 |
| Rosuvastatin Calcium | 138 | $1,909 |
| Levothyroxine Sodium | 94 | $1,147 |
| Metoprolol Succinate | 44 | $978 |
| Ezetimibe | 47 | $951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $324 | $53,96454 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $103 | $48,94059 claims |
| PfizerEliquis | $43 | $26,70838 claims |
| Lilly USA, LLCMounjaro | $270 | $22,73720 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $54 | $16,31833 claims |
| Esperion Therapeutics, Inc.Nexletol | $42 | $5,37614 claims |
| MerckJanuvia | $16 | $5,26511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Lufkin
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Kelly BrassilHouston$194K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Monica WhiteLongview$118K
- Onna FeuchterSouthlake$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.